Who are Imfinzi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bavencio, Tecentriq, Imfinzi, Unloxcyt, AVELUMAB, DURVALUMAB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/durvalumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Imfinzi — Competitive Intelligence Brief

Imfinzi (durvalumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Programmed Death Ligand-1 Blocker [EPC]. Area: Oncology.

marketed Programmed Death Ligand-1 Blocker [EPC] Programmed cell death 1 ligand 1 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Imfinzi (durvalumab) — AstraZeneca. Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Imfinzi TARGET	durvalumab	AstraZeneca	marketed	Programmed Death Ligand-1 Blocker [EPC]	Programmed cell death 1 ligand 1	2017-01-01
Bavencio	avelumab	Merck KGaA	marketed	Programmed Death Ligand-1 Blocker [EPC]	Programmed cell death 1 ligand 1	2017-01-01
Tecentriq	atezolizumab	Roche	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death 1 ligand 1	2016-01-01
Imfinzi	Imfinzi	University Medical Center Groningen	marketed		Programmed cell death 1 ligand 1
Unloxcyt	COSIBELIMAB	Checkpoint Therapeutics Inc	marketed	Programmed Death Ligand-1 Blocker [EPC]	Pd-1	2024-01-01
AVELUMAB	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Programmed Death Ligand-1 Blocker [EPC] class)

· 2 drugs in this class
AstraZeneca · 1 drug in this class
CHECKPOINT THERAPEUTICS INC · 1 drug in this class
Checkpoint Therapeutics Inc · 1 drug in this class
Merck KGaA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imfinzi — Competitive Intelligence Brief. https://druglandscape.com/ci/durvalumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab